At a glance
ClinicalIndex Comparison RecordN/ACompleted· 332 enrolled
Drug / intervention
nSTRIDE APS +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Double-Blind, Randomized, Saline-Controlled Study of a Single, Intra-articular Injection of Autologous Protein Solution in Patients With Knee Osteoarthritis
In Brief
A clinical study evaluating nSTRIDE APS and Saline for Osteoarthritis. Completed, enrolled 332 participants across 27 sites.
Detailed Summary
A double-blind, multicenter, randomized, controlled trial (RCT) that will evaluate the efficacy of a single dose of Autologous Protein Solution (APS) in patients with Osteoarthritis (OA) of the knee.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOsteoarthritis
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedSep 2016
Enrollment StartNov 2016
Primary CompletionJul 2019
Study CompletionJun 2020
TodayJul 2026
First PostedSep 19, 2016
Enrollment StartNov 1, 2016
Primary CompletionJul 1, 2019
Study CompletionJun 1, 2020
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 9.8 years ago
Interventions
nSTRIDE APSdevice
single intra-articular injection
Salinedevice
single intra-articular injection